Introduction
============

Native low-density lipoprotein (LDL) particles become pathogenic,[@b1-dmso-7-513] immunogenic,[@b2-dmso-7-513],[@b3-dmso-7-513] and atherogenic[@b4-dmso-7-513],[@b5-dmso-7-513] when oxidized. Current clinical research points to the oxidation of LDL as a causative and initiating event in many pathological conditions.[@b6-dmso-7-513] The serum titer of autoantibodies to oxidized LDL (oxLDL) has been shown to be associated with and may predict progression of atherosclerosis,[@b7-dmso-7-513] myocardial infarction, and coronary artery disease.[@b8-dmso-7-513] Anti-oxLDL antibodies are also shown to be independent predictors for development of type 2 diabetes mellitus (DM) in women.[@b9-dmso-7-513]

Oxidative modification of LDL is an irreversible process that leads to alterations in lipoprotein structure and function, and takes place in two stages. In the first stage (mild oxidation), LDL lipids are oxidized without any transformation of the molecular structure of apolipoprotein (Apo) B-100. In the second stage (advanced oxidation), LDL lipids are further oxidized, and oxidative changes in amino acids, proteolysis, and cross-linking of Apo B-100 occur.[@b10-dmso-7-513] Therefore, oxLDL exists in multiple forms, characterized by different degrees of oxidation, including minimally modified LDL, which is still recognized by the LDL receptor, and fully or extensively oxLDL, which is recognized by scavenger receptors. Thus, oxLDL might represent the elephant that is described by blind men.[@b11-dmso-7-513] Whereas native LDL has no effect on the immune system, modified lipoproteins are immunogenic.[@b12-dmso-7-513] OxLDL and malondialdehyde-modified LDL (MDA-LDL) are more addressed in biomedical research. Human autoantibodies to oxLDL have been purified and characterized. The predominant isotype of oxLDL antibodies are immunoglobulin (Ig)G1 and IgG3.[@b13-dmso-7-513] The immune complexes formed by oxLDL and their antibodies have been shown to have proinflammatory properties.[@b14-dmso-7-513] Investigation of circulating oxLDL antibodies for their protective or pathogenic role is controversial. Considerable debate has arisen, with some groups suggesting a positive correlation between oxLDL antibody levels and atherosclerosis or vascular disease, and others disagreeing with this correlation and even showing an inverse correlation between these antibodies and cardiovascular disease.

Hunt et al,[@b15-dmso-7-513] Crisby et al,[@b16-dmso-7-513] Lopes-Virella et al,[@b17-dmso-7-513] and others have demonstrated the pathogenic role of oxLDL antibodies and their immune complexes. OxLDL antibodies are able to activate the complement system via the classical pathway and to induce FcR-mediated phagocytosis.[@b17-dmso-7-513] On the other hand, several groups have proposed a protective role for the humoral immune response to modified LDL. Santos et al suggest that circulating anti-oxLDL antibodies could have a protective role in atherosclerosis.[@b18-dmso-7-513] Garrido-Sanchez et al found that patients with coronary disease and disorders of carbohydrate metabolism have much lower levels of IgG anti-oxLDL antibodies than normoglycemic patients,[@b19-dmso-7-513] supporting the protective role of these antibodies. Human anti-oxLDL antibodies play an important role in the regulation of oxLDL levels. Supporting the proposed protective effect, these antibodies have been found in children and healthy adults.[@b20-dmso-7-513]

Recent studies on the prevalence of DM indicate that there were 171 million people with the disease worldwide in the year 2000, and this figure is projected to increase to 366 million by the year 2030.[@b21-dmso-7-513] DM is a strong risk factor for microvascular and macrovascular disease.[@b22-dmso-7-513] Thus, it is associated with reduced life expectancy and significant morbidity.[@b23-dmso-7-513]

The role of oxLDL and their antibodies as a risk factor has attracted considerable attention.[@b24-dmso-7-513] Previous epidemiological research evaluating the possible associations between serum oxLDL antibody levels and nutritional factors showed that oxLDL antibody levels are related to the percentage of kilocalories derived from lipids.[@b25-dmso-7-513] Obesity is a well-known risk factor for diabetes and coronary artery disease. The present study investigated the relationship between anti-oxLDL antibodies and obesity in different glycemic situations.

Subjects and methods
====================

The study sample was selected from the outpatient clinics of the main hospitals and government offices in Makkah Al-Mukarama, Kingdom of Saudi Arabia. The study protocol was approved by the biomedical ethics committee at the Faculty of Medicine, Umm Al-Qura University, Makkah, Kingdom of Saudi Arabi.

Approximately 274 adult male subjects aged 18--55 years agreed to participate and were enrolled, subjected to the study investigations, informed about the nature of the study, and signed their ethical consent. They completed a structured questionnaire, after which measurements of weight, height, and blood pressure were performed, with body mass index (BMI) calculated as weight (kg) divided by height (m^2^).

The study population was classified into three groups according to the recommendations of the American Diabetes Association for diagnosis of diabetes and classification of glucose tolerance.[@b26-dmso-7-513] Group 1 comprised normal nondiabetic subjects, group 2 comprised subjects with impaired glucose tolerance (IGT), and group 3 comprised subjects with type 2 DM. In each group, participants were subcategorized as obese (BMI ≥30) or nonobese (BMI \<30). Potential participants were excluded if they had a known history of coronary heart disease or cardiovascular complications of type 2 DM, had known insulin-dependent DM, were younger than 18 years or older than 55 years, or had conditions with known familial hypercholesterolemia.

Samples were collected from all study participants using standard procedures for collection and storage. Briefly, blood samples were drawn from the antecubital vein into ethylenediamine tetraacetic acid-containing vacuum tubes, for serum, blood was collected in plan tubes and left for 30 minutes, centrifuged for 15 minutes at 3,000 rpm, and the serum sample was obtained. All samples were correctly labeled and sent directly to the biochemistry laboratory.

Measurement protocols
---------------------

### Oxidized low-density lipoproteins

OxLDL levels were measured using a competitive enzyme-linked immunosorbent assay (ELISA) kit (Mercodia AB, Uppsala, Sweden). This protocol uses Holvoet et al monoclonal antibody, 4E6, which is specific for oxidatively modified LDL.[@b27-dmso-7-513] The 4E6 antibody is directed against a conformational epitope in the Apo B-100 of LDL that is generated as a consequence of aldehyde substitution of the lysine residues of Apo B-100. The principle of the procedure is based on the fact that the oxLDL in the sample competes with a fixed amount of oxLDL bound to the microtiter well for binding to the biotin-labeled specific antibodies 4E6. After a washing step, the biotin-labeled antibody bound to the well is detected by horseradish peroxidase-conjugated streptavidin. After a second incubation and an additional washing step, the bound conjugate is detected by reaction with 3,3′,5,5′-tetramethylbenzidine. The reaction is then stopped by adding acid to give a colorimetric end point that is read spectrophotometrically.

### Oxidized low-density lipoprotein antibodies

OxLDL antibodies were measured using a commercially available ELISA kit (IMMCO Diagnostics, Amerhurst, NY, USA). This test kit is designed for research use only. As described by Craig et al,[@b28-dmso-7-513] the test is performed as a solid-phase immunoassay. Microwells are coated with oxLDL antigen followed by a blocking step to reduce nonspecific protein binding during the assay run. Controls, calibrators, and patient serum are incubated in the antigen-coated wells to allow specific antibodies in the samples to bind to the antigen. Unbound antibodies and other serum proteins are removed by washing the microwells. Bound antibodies are detected by adding an enzyme-labeled antihuman IgG conjugate to the microwells. Unbound conjugate is removed by washing. A specific enzyme substrate (3,3′,5,5′-tetramethylbenzidine) is then added to the wells, and the presence of antibodies is detected by a color change. The reaction is stopped, and the intensity of the color change, which is proportional to the concentration of antibody, is read at 450 nm. The results are expressed in ELISA units per milliliter. The interassay and intraassay coefficients of variation range from 5% to 13%.

### Routine biochemistry

Glucose and glycosylated hemoglobin were measured using standard procedures and available commercial kits in a fully automated system (COBAS^®^ Integra 400 Plus, Roche Diagnostics, Indianapolis, IN, USA). All assays were done following the procedures recommended for instrument operation, calibration, quality control, and assay guidelines. The instrument was calibrated using the calibrator for automated systems (Roche Diagnostics). Results were expressed in mg/dL for all parameters, except for glycosylated hemoglobin, which was expressed as a percentage.[@b29-dmso-7-513]

Statistical analysis
--------------------

Descriptive statistics, *t*-tests, and one-way analysis of variance were used to compare the concentrations of oxLDL antibodies and other metabolic parameters between the control, IGT, and type 2 DM groups and between the obese and nonobese subgroups. The Pearson correlation procedure was used to test the correlation between anti-oxLDL antibody levels and BMI. *P*\<0.05 was considered to be statistically significant. All statistical methods were performed using Statistical Package for the Social Sciences for Windows version 20 software (IBM Corporation, Armonk, NY, USA).

Results
=======

The study included 274 men aged 18--55 years who lived in Makka Al-Mukaram. There were 125 normal controls, 77 subjects with IGT, and 72 patients with type 2 DM. As shown in [Table 1](#t1-dmso-7-513){ref-type="table"}, our data indicate an increased mean BMI in the IGT group when compared with the control group and the type 2 DM group (31.1±5.1 kg/m^2^ versus 28.3±4.9 kg/m^2^ and 30.2±5.1 kg/m^2^, respectively; *P*\<0.001). In each group, the mean age of obese and nonobese subjects was similar ([Table 1](#t1-dmso-7-513){ref-type="table"}). Although fasting blood sugar, 2-hour postprandial glucose, and glycosylated hemoglobin showed a significant increase in the IGT and type 2 DM groups compared with controls, there was no significant difference in these parameters between the obese and nonobese subgroups ([Table 1](#t1-dmso-7-513){ref-type="table"}).

OxLDL was found to be significantly increased in the IGT group when compared with controls (*P*\<0.001), with more elevation observed in diabetic subjects. However, when we compared this parameter between obese and nonobese subjects in the same group, there was no significant difference between the means of each subgroup.

Mean anti-oxLDL antibody levels were increased significantly in the IGT group (40.4±17.6 U/L, *P*\<0.001) when compared with controls, and an even greater mean increase was found in the type 2 DM group (55.7±17.8 U/L, *P*\<0.001). Elevated mean levels of these antibodies were found in obese controls (25.4±13.2 U/L) when compared with nonobese controls (17.7±6.4, *P*\<0.001), as shown in [Table 1](#t1-dmso-7-513){ref-type="table"}. In the IGT group, mean anti-oxLDL antibody levels were also significantly (*P*\<0.01) increased in obese (45.7±21 U/L) compared with nonobese (34.6±9.8 U/L) subjects. The difference in mean anti-oxLDL antibody levels between the obese and nonobese subgroups was not significant in the type 2 DM group ([Figure 1](#f1-dmso-7-513){ref-type="fig"}).

[Figure 2](#f2-dmso-7-513){ref-type="fig"} shows a positive correlation between oxLDL levels and oxLDL antibody levels in the study population (*r*=0.59, *P*\<0.001). A positive correlation also existed between oxLDL antibodies and BMI in the control group (*r*=0.46, *P*\<0.001), the IGT group (*r*=0.51, *P*\<0.001), the type 2 DM group (*r*=0.46, *P*\<0.001), and in the whole study population (*r*=0.44, *P*\<0.001) as shown in [Figure 3](#f3-dmso-7-513){ref-type="fig"}.

Discussion
==========

Modified lipoproteins are immunogenic in humans and in animal models.[@b12-dmso-7-513] Of all the modified forms of LDL, oxLDL and MDA-LDL are the most extensively investigated in biomedical research. OxLDL, because they are no longer recognized by LDL receptors, form immunogenic epitopes leading to formation of antibodies; the predominant isotype of oxLDL antibodies is IgG, of subclasses 1 and 3.[@b13-dmso-7-513] These antibodies are attracting considerable attention in biomedical research in terms of their pathogenic or protective clinical role and the biochemical and anthropometric measures associated with elevated levels of these antibodies. The present study investigated the association between increased levels of anti-oxLDL antibodies and obesity in different glycemic situations.

Our data indicated higher levels of anti-oxLDL antibodies in the type 2 DM group (*P*\<0.001). This finding cannot answer the question about the pathogenic or protective role of these antibodies, but it may give some clues. Diabetic individuals are believed to have a higher risk of cardiovascular disease than those without diabetes, and higher concentrations of anti-oxLDL antibodies seem to be pathogenic via formation of immune complexes. There is a significant body of evidence supporting a pathogenic role for immune complexes formed by oxLDL (oxLDL-IC) and their corresponding antibodies, in both atherosclerosis and macrovascular disease. OxLDL antibodies are able to activate the complement system via the classical pathway and induce FcR-mediated phagocytosis.[@b17-dmso-7-513] Hunt et al indicate that high levels of oxLDL-IC and advanced glycation end products (AGE)-LDL-IC are important predictors of carotid intima-medial thickening in patients with type 1 diabetes.[@b15-dmso-7-513] Crisby et al showed that MDA-LDL IgM levels were associated with an increased risk of cardiovascular events in patients with a previous myocardial infarction.[@b16-dmso-7-513] Further, increased levels of oxLDL-IC have been found to be associated with development of coronary artery calcification.[@b17-dmso-7-513]

In contrast, Garrido-Sanchez et al found that patients with coronary disease and disorders of carbohydrate metabolism have much lower levels of IgG anti-oxLDL antibodies than normoglycemic patients,[@b19-dmso-7-513] supporting the protective role of these antibodies. Our data indicate elevated levels in individuals with disorders of carbohydrate metabolism, ie, the type 2 DM and IGT groups, when compared with normoglycemic subjects. However, the sample studied by Garrido-Sanchez et al comprised hospitalized patients scheduled to undergo percutaneous coronary intervention, whereas coronary heart disease was an exclusion criterion in the present study.

In each study group, anti-oxLDL antibodies were found to be increased in obese subjects when compared with their nonobese counterparts, although there were no significant differences in age or other metabolic parameters in the same group. The difference in oxLDL concentrations between the obese and nonobese subgroups was significant in the control group (*P*\<0.001) and in the IGT group (*P*\<0.01) as shown in [Figure 1](#f1-dmso-7-513){ref-type="fig"}, but was not significant in the type 2 DM group. This may be due to the weight loss often found in patients with diabetes.

The findings of the current study show a positive correlation between oxLDL levels and oxLDL antibody levels, as shown in [Figure 2](#f2-dmso-7-513){ref-type="fig"}. Human anti-oxLDL antibodies play an important role in regulation of oxLDL levels. Supporting their proposed protective effect, these antibodies have been found in children and in healthy adults.[@b20-dmso-7-513]

BMI was found to be significantly increased in the type 2 DM group (*P*\<0.05) and in the IGT group (*P*\<0.001) compared with controls. Obesity is widely considered to be a strong risk factor for type 2 diabetes and its cardiovascular complications and is an independent risk factor for cardiovascular disease itself.[@b30-dmso-7-513] Overweight and obesity are associated with higher lipoprotein oxidation, both abdominal and general obesity were shown to be independently associated with circulating oxLDL, weight reduction may potentially reduce oxLDL,[@b31-dmso-7-513] especially in patients with metabolic syndrome.[@b32-dmso-7-513] Previous studies have suggested a correlation between anti-oxLDL autoantibodies and anthropometric variables, making anti-oxLDL concentration a potential biochemical indicator of risk of metabolic syndrome.[@b33-dmso-7-513] Our results show a significant positive correlation between BMI and oxLDL antibodies. This may explain the increased prevalence of type 2 DM and cardiovascular complications in obese subjects reported in many previous studies. The strong link between oxLDL concentration and risk of cardiovascular disease is well established, including its vital role in formation of foam cells. In the present study, a positive correlation between anti-oxLDL antibodies and BMI was found in all study groups, as shown in [Figure 3](#f3-dmso-7-513){ref-type="fig"}. Weight loss recommendations in previous studies may also be beneficial for reduction of oxLDL antibodies, the immune complexes formed, and the ensuing complications of diabetes.

This study has several limitations. Our subjects were adult Saudi males, so we do not know if our findings are relevant in other ethnic populations, children, or women. Different procedures and kits are available for measuring oxLDL and oxLDL antibodies, and our results represent parameters measured according to the protocols described in the methodology section. The sample size was relatively small, and did not include measurement of cardiovascular endpoints. Large studies addressing clinical outcomes are needed to confirm our findings.

Conclusion
==========

Increased levels of anti-oxLDL antibodies are associated with obesity and are positively correlated with BMI. Anti-oxLDL antibodies are increased in individuals with IGT or type 2 DM when compared with subjects who have normal glucose tolerance.
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###### 

Results for age, BMI, glucose tolerance, lipid profile, oxLDL, and oxLDL antibodies in the study groups

                           Control (n=125)   IGT (n=77)                                              Type 2 DM (n=72)                                                                       
  ------------------------ ----------------- ------------------------------------------------------- ------------------ ------------------------------------------------------- ----------- -----------
  Age, years               34±9              34±8                                                    40±10              39±9                                                    42±8        43±10
  34±9                                       39±10[cc](#tfn5-dmso-7-513){ref-type="table-fn"}                           42±9[c](#tfn4-dmso-7-513){ref-type="table-fn"}                      
  BMI, kg/m^2^             25.5±2.7          33.6±3.4                                                27.0±2.3           34.9±3.7                                                26.3±2.5    34.1±4.0
  28.3±4.9                                   31.1±5.1                                                                   30.2±5.1                                                            
  FBS, mg/dL               91±10             91±11                                                   116±23             116±19                                                  196±67      189±63
  91±10                                      116±21[cc](#tfn5-dmso-7-513){ref-type="table-fn"}                          193±65[cc](#tfn5-dmso-7-513){ref-type="table-fn"}                   
  2-hour PP, mg/dL         108±18            113±18                                                  171±15             163±21                                                  289±67      305±88
  109±18                                     167±19[cc](#tfn5-dmso-7-513){ref-type="table-fn"}                          298±79[cc](#tfn5-dmso-7-513){ref-type="table-fn"}                   
  HbA~1c~, %               5.0±0.6           5.1±0.7                                                 6.9±1.2            6.5±1.3                                                 8.7±1.8     8.3±2.4
  5.0±0.6                                    6.7±1.2[cc](#tfn5-dmso-7-513){ref-type="table-fn"}                         8.5±2.1[cc](#tfn5-dmso-7-513){ref-type="table-fn"}                  
  Cholesterol, mg/dL       199±57            201±45                                                  236±63             244±55                                                  271±88      253±68
  200±53                                     240±59[cc](#tfn5-dmso-7-513){ref-type="table-fn"}                          262±79[cc](#tfn5-dmso-7-513){ref-type="table-fn"}                   
  TG, mg/dL                165±81            151±73                                                  227±147            201±83                                                  266±184     231±126
  160±78                                     213±118[c](#tfn4-dmso-7-513){ref-type="table-fn"}                          248 ±158[cc](#tfn5-dmso-7-513){ref-type="table-fn"}                 
  HDL, mg/dL               48.8±16           48.7±14.8                                               49.5±15            56.6±18                                                 48.2±17.2   44.7±14.2
  48.7±16                                    53.2±17                                                                    46.5±16                                                             
  LDL, mg/dL               116±32            121±29                                                  140±43             142±32                                                  156±50      149±48
  118±31                                     141±38[cc](#tfn5-dmso-7-513){ref-type="table-fn"}                          153±49[cc](#tfn5-dmso-7-513){ref-type="table-fn"}                   
  LDL/HDL                  2.6±0.9           2.6±0.8                                                 3.1±1.5            2.8±1.1                                                 3.5±1.3     3.5±1.5
  2.6±0.9                                    2.9±1.3                                                                    3.5±1.4[cc](#tfn5-dmso-7-513){ref-type="table-fn"}                  
  OxLDL (U/L)              71±27.2           77±28.1                                                 109±20.5           108±26.5                                                143±25.3    144±18.3
  73.5±27.5                                  108.7±23.7[cc](#tfn5-dmso-7-513){ref-type="table-fn"}                      143.5±21.9[cc](#tfn5-dmso-7-513){ref-type="table-fn"}               
  OxLDL antibodies (U/L)   17.7±6.4          25.4±13.2[a](#tfn2-dmso-7-513){ref-type="table-fn"}     34.6±9.8           45.7±21[b](#tfn3-dmso-7-513){ref-type="table-fn"}       51.8±15.2   59.6±19.4
  20.4±10.0                                  40.4 ±17.6[cc](#tfn5-dmso-7-513){ref-type="table-fn"}                      55.7±17.8[cc](#tfn5-dmso-7-513){ref-type="table-fn"}                

**Notes:** Results are expressed as the mean ± standard deviation.

*P*\<0.001 when obese compared with nonobese in the control group;

*P*\<0.01 when obese compared with nonobese in the IGT group;

*P*\<0.01 when compared with the control group;

*P*\<0.001 when compared with the control group.

**Abbreviations:** BMI, body mass index; FBS, fasting blood sugar; PP, postprandial blood sugar; TG, triglycerides; oxLDL, oxidized low-density lipoprotein; DM, diabetes mellitus; HDL, high-density lipoprotein; IGT, impaired glucose tolerance; LDL, low density lipoprotein; HbA~1c~, Hemoglobin A~1c~.
